Next Article in Journal
Recent Advances in Proteomic Studies of Adipose Tissues and Adipocytes
Next Article in Special Issue
An Epigenetic Regulator: Methyl-CpG-Binding Domain Protein 1 (MBD1)
Previous Article in Journal
tRNA Biology in Mitochondria
Previous Article in Special Issue
Tumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(3), 4560-4580; doi:10.3390/ijms16034560

Roles of Ubiquitination and SUMOylation on Prostate Cancer: Mechanisms and Clinical Implications

Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN 37208, USA
*
Author to whom correspondence should be addressed.
Academic Editor: William Chi-Shing Cho
Received: 14 January 2015 / Revised: 9 February 2015 / Accepted: 12 February 2015 / Published: 27 February 2015
(This article belongs to the Collection Advances in Molecular Oncology)
View Full-Text   |   Download PDF [752 KB, uploaded 3 March 2015]   |  

Abstract

The initiation and progression of human prostate cancer are highly associated with aberrant dysregulations of tumor suppressors and proto-oncogenes. Despite that deletions and mutations of tumor suppressors and aberrant elevations of oncogenes at the genetic level are reported to cause cancers, emerging evidence has revealed that cancer progression is largely regulated by posttranslational modifications (PTMs) and epigenetic alterations. PTMs play critical roles in gene regulation, cellular functions, tissue development, diseases, malignant progression and drug resistance. Recent discoveries demonstrate that ubiquitination and SUMOylation are complicated but highly-regulated PTMs, and make essential contributions to diseases and cancers by regulation of key factors and signaling pathways. Ubiquitination and SUMOylation pathways can be differentially modulated under various stimuli or stresses in order to produce the sustained oncogenic potentials. In this review, we discuss some new insights about molecular mechanisms on ubiquitination and SUMOylation, their associations with diseases, oncogenic impact on prostate cancer (PCa) and clinical implications for PCa treatment. View Full-Text
Keywords: posttranslational modifications; ubiquitination; SUMOylation; prostate cancer posttranslational modifications; ubiquitination; SUMOylation; prostate cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chen, Z.; Lu, W. Roles of Ubiquitination and SUMOylation on Prostate Cancer: Mechanisms and Clinical Implications. Int. J. Mol. Sci. 2015, 16, 4560-4580.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top